课题基金 / 基金详情

A new curcumin analogue with potent suppressive activity in pancreatic cancer

A new curcumin analogue with potent suppressive activity in pancreatic cancer
一种新的姜黄素类似物，对胰腺癌具有有效的抑制活性
批准号：
7740282
负责人：
Jiayuh Lin
金额：
$7.63万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-08-01 至 2011-07-31
来源：
https://reporter.nih.gov/project-details/7740282
关键词：
Advanced Malignant NeoplasmBiological AvailabilityCancer cell lineCell LineCell ProliferationCell SurvivalCellsChemopreventive AgentClinical TrialsCountryCurcuminDiagnosisDoseDrug resistanceExcisionExhibitsExocrine pancreasGoalsGrowthHumanIn VitroIndividualIntervention StudiesLifeLocalized DiseaseMalignant NeoplasmsMalignant neoplasm of pancreasModelingMusNeoplasm MetastasisNew AgentsNormal CellOncogenicOperative Surgical ProceduresPancreatic carcinomaPathway interactionsPatientsPhosphorylationPlayProto-Oncogene Proteins c-aktRadiation therapyRoleSignal TransductionStagingStat3 proteinSurvival RateTestingTherapeuticTherapeutic AgentsTimeToxic effectTumor VolumeUnited StatesXenograft Modelanalogangiogenesiscancer cellcancer typechemotherapyeffective therapyin vivoinhibitor/antagonistinnovationlymph nodesmortalitymouse modelneoplastic cellnotch proteinnovelnovel therapeuticsoutcome forecastoverexpressionpancreatic neoplasmpre-clinicalpreclinical studypublic health relevanceresponsesmall moleculetherapeutic targettumortumor growth

项目摘要

项目成果

Jiayuh Lin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Several oncogenic pathways are typical overexpressed and activated in pancreatic cancer, which include AKT, Signal Transducer and Activator of Transcription 3 (STAT3), Notch-1, and NF-?B. An effective therapeutic agent may need to exhibit the capacity to inhibit these pathways. STAT3, Notch-1, NF-?B, and AKT pathways are among the major oncogenic pathways activated in pancreatic cancer. These four oncogenic pathways are considered to play critical roles in growth, survival, invasion, angiogenesis, and other functions in pancreatic cancer and thereby emerged as attractive therapeutic targets for this cancer. We proposed to evaluate the inhibitory efficacy of GO-Y030, a new and more potent analogue of the dietary agent, curcumin. Our preliminary results in this proposal demonstrated for the first time that GO-Y030 is approximately 26-397 times more potent than curcumin in inhibiting pancreatic cancer cell viability as well as more potent than cu cell lines. We will also examine whether the expression of STAT3, AKT, and Notch-1 can rescue the inhibitory effects of GO-Y030 in pancreatic cancer cells. In specific aim 2, we will evaluate the inhibitory efficacy of GO-Y030 to suppress PANC-1, MIA-PACA-2, and BxPC-3 pancreatic cancer cells in orthotopic tumor model. Pancreatic cancer is one of the most serious types of cancer and there is a critical need to develop more effective therapeutic agents for pancreatic cancer. Our proposed studies, if successful, will provide a promising potential using GO-Y030 as a novel therapeutic agent for pancreatic cancer with the ultimate goal to reduce the mortality of pancreatic cancer and extending the quality of healthy life for people in this country and around the world. PUBLIC HEALTH RELEVANCE: Each year about 32,000 individuals in the United States are diagnosed with pancreatic cancer. Cancer of the exocrine pancreas is rarely curable and has an overall survival rate of less than 4%. The. itical need for better treatment approaches for pancreatic cancer. The objectives of this proposal are to evaluate the inhibitory efficacy of a new and highly potent curcumin analogue, GO-Y030 in human pancreatic cancer cells in vitro and in a mouse orthotopic tumor model. These results will provide the pre- clinical activities of GO-Y030 as a potential therapeutic agent for more effective treatment for pancreatic cancer
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
  • 批准号：
    10365726
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    2022
  • 负责人：
    Jiayuh Lin
  • 依托单位：
    BALTIMORE VA MEDICAL CENTER
Co-Targeting IL-6 and CDK4/6 Pathways as a Novel Approach of Preventive Therapy for Triple-Negative Breast Cancer
  • 批准号：
    10655282
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    2022
  • 负责人：
    Jiayuh Lin
  • 依托单位：
    BALTIMORE VA MEDICAL CENTER
A novel STAT3-selective inhibitor for medulloblastoma therapy
Repositioning Bazedoxifene as a novel IL-6/GP130 inhibitor for sarcoma therapy
海外基金